Category - Developments

Developments

Trinity achieves breakthrough trial results for next-gen CGM sensor

Trinity Biotech (NASDAQ: TRIB) has announced compelling clinical trial results demonstrating a major technical breakthrough and de-risking the commercial pathway for its next-generation continuous glucose monitoring...

August 12, 2025

Developments

IGC reports positive preclinical data on IGC-M3 in Alzheimer’s

IGC Pharma (NYSE: IGC) has announced promising preclinical results of its novel small molecule, IGC-M3, designed to address multiple biological drivers of Alzheimer’s disease. According to IGC, IGC-M3 demonstrated...

August 12, 2025

Developments

Perimeter sees 100% revenue growth in Q2-2025; reduces operating costs by ~30%; adds to leadership team; and creates IAB

Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX: PYNKF) announced that it anticipates total revenue for the second quarter of 2025 to be approximately $500,000, representing YoY growth of approximately 100%...

August 11, 2025

Developments

NRx’s NRC-100 receives Fast Track Designation for suicide ideation in depression

NRx Pharmaceuticals (NASDAQ: NRXP) has announced that the FDA has granted NRC-100 Fast Track Designation as a standalone drug for the treatment of suicidal ideation in patients with depression, including bipolar...

August 11, 2025

Developments

FDA approves PharmaTher’s KETARx for surgical pain management

PharmaTher Holdings (QTCQB: PHRRF; CSE: PHRM) has announced that the FDA has approved its ketamine product, KETARx, for use in surgical pain management. According to PharmaTher, the approval positions the company to...

August 11, 2025

Developments

Modular announces next-gen Pivot insulin pump at ADCES

Modular Medicine (NASDAQ: MODD) has announced its participation at the Association of Diabetes Care & Education Specialists (ADCES) Conference, August 8 to 11, 2025, where it will debut a coming soon campaign for...

August 8, 2025

Developments

Orchestra launches FDA-approved study protocol expanding patient eligibility criteria

Orchestra BioMed (NASDAQ: OBIO) has announced the roll out of an FDA-approved protocol update that enables a significant expansion in patient eligibility criteria for enrollment of its BACKBEAT study evaluating AVIM...

August 8, 2025

Developments

IDMC gives Elicio green light to continue study of ELI-002 7P in PDAC

Elicio Therapeutics (NASDAQ: ELTX) has announced that the Independent Data Monitoring Committee (IDMC) has recommended that its Phase 2 AMPLIFY-7P study in mutant KRAS (mKRAS)-driven pancreatic ductal adenocarcinoma...

August 5, 2025

Developments

Cadrenal reveals clinical trial plans for tecarfarin in ESKD

Cadrenal Therapeutics (NASDAQ: CVKD) has announced clinical trial initiation plans for its lead late-stage candidate, tecarfarin, for the treatment of patients with end-stage kidney disease (ESKD) transitioning to...

August 5, 2025

Developments

Perimeter joins a select group of medtech innovators in the NVIDIA Connect program

In a LinkedIn post today, Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) revealed that it is now a member of the NVIDIA Connect Program. The company joins other medtech innovators that have recently been accepted...

July 30, 2025

Category - Developments

Subscribe